Literature DB >> 12768439

Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3).

Andreas Lazar1, Dirk Gründemann2, Reinhard Berkels2, Dirk Taubert2, Tim Zimmermann2, Edgar Schömig2.   

Abstract

The extraneuronal monoamine transporter EMT (HGNC Nomenclature SLC22A3) is the molecular correlate of the classical uptake(2) system responsible for the non-neuronal inactivation of circulating and centrally released catecholamines. Because of its functional profile and expression pattern, EMT is regarded as a candidate gene for diseases related to the sympathetic nervous system and neuropsychiatric disorders. We describe the first investigation of the genetic variability of the EMT gene in human. Six single-nucleotide substitutions and one deletion were detected within the assumed core promoter, the exonic and flanking intronic sequences and the 3'-untranslated region in 100 Caucasian individuals. No amino acid changes were found and Tajima's D was positive (D=2.91; P<0.01). However, the synonymous nucleotide substitution 1233G-->A might serve as a cryptic splice acceptor site. Analysis of linkage disequilibrium between polymorphisms yielded 12 possible haplotypes accounting for more than 90% of all haplotypes. Knowledge of the sequence variation and frequency of the underlying polymorphisms in this member of the amphiphilic solute facilitator family of transporters provides the basis for subsequent association studies and candidate gene approaches.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12768439     DOI: 10.1007/s10038-003-0015-5

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  34 in total

1.  DnaSP version 3: an integrated program for molecular population genetics and molecular evolution analysis.

Authors:  J Rozas; R Rozas
Journal:  Bioinformatics       Date:  1999-02       Impact factor: 6.937

2.  The extraneuronal monoamine transporter exists in human central nervous system glia.

Authors:  E Schömig; H Russ; K Staudt; F Martel; M Gliese; D Gründemann
Journal:  Adv Pharmacol       Date:  1998

3.  Removal of circulating catecholamines by extraneuronal amine transport systems.

Authors:  K H Graefe; B Friedgen; R Wölfel; E Schömig
Journal:  Adv Pharmacol       Date:  1998

4.  Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency.

Authors:  J R Shannon; N L Flattem; J Jordan; G Jacob; B K Black; I Biaggioni; R D Blakely; D Robertson
Journal:  N Engl J Med       Date:  2000-02-24       Impact factor: 91.245

5.  Statistical method for testing the neutral mutation hypothesis by DNA polymorphism.

Authors:  F Tajima
Journal:  Genetics       Date:  1989-11       Impact factor: 4.562

6.  Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.

Authors:  K P Lesch; D Bengel; A Heils; S Z Sabol; B D Greenberg; S Petri; J Benjamin; C R Müller; D H Hamer; D L Murphy
Journal:  Science       Date:  1996-11-29       Impact factor: 47.728

7.  Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter.

Authors:  T Pacholczyk; R D Blakely; S G Amara
Journal:  Nature       Date:  1991-03-28       Impact factor: 49.962

8.  Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.

Authors:  Maya K Leabman; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Douglas Stryke; Thomas E Ferrin; Joseph DeYoung; Travis Taylor; Andrew G Clark; Ira Herskowitz; Kathleen M Giacomini
Journal:  Pharmacogenetics       Date:  2002-07

9.  Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A.

Authors:  H G Brunner; M Nelen; X O Breakefield; H H Ropers; B A van Oost
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

10.  Involvement of the central noradrenergic system in cholinergic stimulation of the pituitary-adrenal response.

Authors:  J Bugajski; J Borycz; A Gadek-Michalska
Journal:  J Physiol Pharmacol       Date:  1998-06       Impact factor: 3.011

View more
  7 in total

Review 1.  Regulation of organic cation transport.

Authors:  Giuliano Ciarimboli; Eberhard Schlatter
Journal:  Pflugers Arch       Date:  2004-11-16       Impact factor: 3.657

2.  Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin.

Authors:  Ligong Chen; Bradley Pawlikowski; Avner Schlessinger; Swati S More; Doug Stryke; Susan J Johns; Michael A Portman; Eugene Chen; Thomas E Ferrin; Andrej Sali; Kathleen M Giacomini
Journal:  Pharmacogenet Genomics       Date:  2010-11       Impact factor: 2.089

Review 3.  Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution.

Authors:  Thomas Gerloff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

Review 4.  Drug transporters in the human blood-placental barrier.

Authors:  Kirsi Vähäkangas; Päivi Myllynen
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

5.  The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway.

Authors:  Mei Cui; Radha Aras; Whitney V Christian; Phillip M Rappold; Mamata Hatwar; Joseph Panza; Vernice Jackson-Lewis; Jonathan A Javitch; Nazzareno Ballatori; Serge Przedborski; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205

6.  Evaluation of genetic variations in organic cationic transporter 3 in depressed and nondepressed subjects.

Authors:  Nina Hengen; Mitsi H Lizer; Robert S Kidd
Journal:  ISRN Pharmacol       Date:  2011-08-14

7.  Association between the synonymous variant organic cation transporter 3 (OCT3)-1233G>A and the glycemic response following metformin therapy in patients with type 2 diabetes.

Authors:  Seyyedeh Raheleh Hosseyni-Talei; Abdolkarim Mahrooz; Mohammad Bagher Hashemi-Soteh; Maryam Ghaffari-Cherati; Ahad Alizadeh
Journal:  Iran J Basic Med Sci       Date:  2017-03       Impact factor: 2.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.